Patent · US Active

Factor VIII conjugates

US9364520B2 · kind B2 · utility

2Cited by

24References

9Claims

0Family size

Assignee

BAYER HEALTHCARE LLC · DE

Inventors

Clark Pan · Sudbury, US
John E. Murphy · Mobile, US
Baisong Mei · Newton, US
Jonathan S. Strauss · Los Angeles, US
Hendri Tjandra · Union City, US
Jianmin Chen · New York, US
Thomas Barnett · East Haven, US
Liang Tang · Sunnyvale, US
Deqian Wang · Concord, US

Key dates

Filing date	Aug 13, 2009
Grant date	Jun 14, 2016
Priority date	—
Expiry date	Aug 25, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.